


 Cite this: *RSC Adv.*, 2024, **14**, 38403

Design, synthesis, and antiproliferative activity of new 1,2,3-triazole/quinazoline-4-one hybrids as dual EGFR/BRAF^{V600E} inhibitors†

 Amira M. Mohamed,^a Ola M. F. Abou-Ghadir,^a Yaser A. Mostafa,^a Zainab M. Almarhoon,^b Stefan Bräse^b ^{*c} and Bahaa G. M. Youssif^b ^{*a}

A novel series of 1,2,3-triazole/quinazoline-4-one hybrids (**8a–t**) were designed and synthesized as dual-targeted antiproliferative agents. Compounds **8a–t** were evaluated for their antiproliferative efficacy against a panel of four cancer cell lines. The results indicated that most of the evaluated compounds exhibited strong antiproliferative activity, with **8f**, **8g**, **8h**, **8j**, and **8l** demonstrating the highest potency. These five compounds were investigated as EGFR and BRAF^{V600E} inhibitors. The *in vitro* tests showed that compounds **8g**, **8h**, and **8j** are strong antiproliferative agents that might work as dual EGFR/BRAF^{V600E} inhibitors. Compounds **8g** and **8h** were further examined as activators of caspases 3, 8, and Bax and down-regulators of the anti-apoptotic protein Bcl2. The results indicated that the studied compounds had considerable apoptotic antiproliferative action. The investigation of the cell cycle and apoptosis revealed that compound **8g** induces cell cycle arrest during the G1 phase transition. Molecular docking experiments are thoroughly examined to validate the binding interactions of the most active hybrids with the active sites of EGFR and BRAF^{V600E}. The data indicated that the examined compounds can efficiently engage with essential amino acid residues in both kinases.

 Received 16th September 2024
 Accepted 18th November 2024

 DOI: 10.1039/d4ra06694d
rsc.li/rsc-advances

1. Introduction

Cancer is abnormal cellular proliferation resulting from an imbalance between cell division and apoptosis.^{1,2} Despite the availability of different therapeutic modalities, including surgical intervention, radiation, immunotherapy, and chemotherapy, cancer continues to be a contentious clinical issue. Nevertheless, effective chemotherapeutic agents with minimal side effects have garnered significant interest.^{3,4} Elucidating and revealing cancer's molecular and cellular roots has significantly contributed to advancing cancer therapies. Currently, cancer therapy identifies membrane receptors of the tyrosine kinase (TK) family as primary targets.^{5,6} The epidermal growth factor (EGF) family includes important membrane receptors, with the epidermal growth factor receptor (EGFR) getting much attention. It has been found that blocking EGFR signaling is recognized as a potent therapeutic strategy.^{7,8}

Clinical studies have shown that combining B-Rapidly Accelerated Fibrosarcoma (B-raf proto-oncogene or BRAF) and tyrosine kinase (TK) inhibitors effectively stops tumor growth and overcomes resistance. Concomitant use of EGFR inhibitors may mitigate resistance to vemurafenib, a mutant BRAF (BRAF^{V600E}) inhibitor, in thyroid cancer.⁹ This combination has also demonstrated encouraging outcomes in BRAF^{V600E} colorectal cancer.¹⁰ Furthermore, researchers have found several compounds *in vitro* that contain the critical pharmacophoric groups required to inhibit tyrosine kinases, such as epidermal growth factor receptor/vascular endothelial growth factor receptor-2 (EGFR/VEGFR-2) and BRAF.^{11,12} For example, compound **I** (Fig. 1) inhibited wild-type BRAF and EGFR, exhibiting IC₅₀ values in the nanomolar range. Furthermore, imidazo[1,2-*b*]pyridazine **II** inhibited BRAF and VEGFR-2.

Heterocyclic compounds have yielded a plethora of commercialized medicines and bioactive substances, and their notable cytotoxicity has been essential in the design and production of anticancer agents.^{13,14} Consequently, quinazolines have garnered significant attention owing to their efficacy and specificity.^{15,16} Quinazolines' anticancer properties can be traced back to Paganini (vaccine), a naturally occurring quinazoline discovered in 1888.¹⁷ Gefitinib, erlotinib, and lapatinib are FDA-approved quinazoline-based anticancer agents that function as EGFR inhibitors^{18–20} (Fig. 2).

On the other hand, 1,2,3-triazoles are important scaffolds often synthesized using the 1,3-dipolar cycloaddition reaction

^aPharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt. E-mail: bgyoussif2@gmail.com; bahaa.youssif@pharm.assu.edu.eg

^bDepartment of Chemistry, College of Science, King Saud University, Riyadh 11451, Saudi Arabia

^cInstitute of Biological and Chemical Systems, IBCS-FMS, Karlsruhe Institute of Technology, 76131 Karlsruhe, Germany. E-mail: braese@kit.edu

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d4ra06694d>




Fig. 1 Structures of dual inhibitors BRAF/TKs compounds I and II.




Fig. 2 Structures of FDA-approved quinazoline-based anticancer agents.

(click chemistry reaction) between terminal acetylenes and azides.^{21–23} The anticancer activity of 1,2,3-triazoles has garnered significant attention regarding their therapeutic properties.^{24–26} In a recent publication from our lab,²⁴ we describe the discovery of a novel class of 1,2,3-triazole/quinoline hybrids as antiproliferative compounds that act as multi-targeted inhibitors. Most novel compounds demonstrated considerable antiproliferative activity against a panel of four cancer cell lines. With IC₅₀ values of 57 nM for EGFR, 68 nM for BRAF^{V600E}, and 9.70 nM for EGFR^{T790M}, compound III (Fig. 3) was the most effective at blocking these three proteins. The apoptotic assay results indicated that compound III functions

as caspase-3, 8, and Bax activator while down-regulating the antiapoptotic protein Bcl2.

In another publication,²⁶ we report compound IV (Fig. 3), a 1,2,3-triazole/1,2,4-oxadiazole hybrid, as a potent apoptotic antiproliferative agent that may function as dual inhibitors of EGFR and VEGFR-2.

1.1. Rational design

Recently,²⁷ we reported a series of 1,2,4-oxadiazole/quinazoline-4-one hybrids (Va–o, Fig. 4) designed as antiproliferative agents targeting EGFR/BRAF^{V600E}. The results indicated that most





Fig. 3 Structures of 1,2,3-triazole-based derivatives III and IV.



Previously published compounds (Va-o)

EGFR/BRAF inhibitors

Fig. 4 Structures of previously published quinazoline-4-one derivatives Va–o and new target compounds 8a–t.



Newly synthesized compounds (8a-t)

EGFR/BRAF inhibitors

evaluated compounds exhibited strong antiproliferative activity, with **Vb**, **Vc**, **Vh**, **Vk**, and **VI** demonstrating the highest potency. We tested these compounds as EGFR and BRAF^{V600E} inhibitors and discovered they are good at stopping cell growth and may work as dual inhibitors of EGFR and BRAF^{V600E}.

As recently discovered, hybrid molecules have addressed several challenges associated with traditional drugs, including side effects and multidrug resistance (MDR).²⁸ In support of our efforts to develop anticancer drugs with dual or multi-targeted mechanisms,^{27,29–35} we synthesized new quinazolin-4-ones coupled to 1,2,3-triazoles (8a–t, Fig. 4). We assessed their anti-proliferative effectiveness against four different cancer cells. The most potent compounds were further tested as dual inhibitors of EGFR/BRAF. Also, the most potent hybrids were investigated for their apoptotic potential as activators of caspase 3,8 and BAX and down-regulators of antiapoptotic Bcl2. Finally, the most potent derivative was tested for cell cycle arrest and apoptosis.

2. Experimental

2.1. Chemistry

General details: see Appendix A (ESI file).†

2.1.1. General procedures for the synthesis of the target compounds (8a–t). To a mixture of (2-propynyl)thioquinazolin-4(3H)-ones (0.85 mmol, 1 eq.) and *p*-azido phenyl derivatives (1.02 mmol, 1.2 eq.) in 20 mL of THF, an aqueous solution (5 mL) of sodium ascorbate (0.03 g, 0.17 mmol, 0.2 eq.) and CuSO₄·5H₂O (0.01 g, 0.0425 mmol, 0.05 eq.) was added. The mixture was refluxed for 24–48 h. After completion of reaction, the solvent was evaporated under vacuum, the precipitate was filtered, washed with cold water, dried and recrystallized by methanol to obtain 8a–t compounds.

2.1.1.1. 2-(((1-Phenyl-1H-1,2,3-triazol-4-yl)methyl)thio)-3-phenyl quinazolin-4(3H)-one (8a). Yield: 0.26 g (74%), white solid, m.p: 136–138 °C, *R*_f. 0.56 (hexane : ethyl acetate, 1 : 2, v/v). ¹H NMR (400 MHz, δ ppm CDCl₃): 8.19 (d, J = 7.8 Hz, 1H, Ar-H), 8.01 (s, 1H, triazole CH), 7.70 (t, J = 7.4 Hz, 1H, Ar-H), 7.61 (d, J = 7.4 Hz, 3H, Ar-H), 7.47–7.37 (m, 5H, Ar-H), 7.36–7.30 (m, 2H, Ar-H), 7.24–7.14 (m, 2H, Ar-H), 4.50 (s, 2H, S-CH₂). ¹³C NMR (100 MHz, δ ppm CDCl₃): 161.71, 156.87, 147.68, 135.52, 135.19, 134.89, 130.18, 129.80, 129.78, 129.44, 129.16, 128.81, 128.44,

127.50, 126.12, 126.01, 120.59, 120.01, 27.25. LC-MS (*m/z*) for: C₂₃H₁₇N₅OS (exact mass = 411.12); calculated [M + H]⁺: 412.12; found [M + H]⁺: 412.00.

2.1.1.2. 2-(((1-(4-Chlorophenyl)-1H-1,2,3-triazol-4-yl)methyl)thio)-3-phenyl quinazolin-4(3H)-one (8b). Yield: 0.29 g (77%), white solid, m.p: 146–148 °C, *R*_f. 0.55 (hexane : ethyl acetate, 1 : 2, v/v). ¹H NMR (400 MHz, δ ppm DMSO-*d*₆): 8.76 (s, 1H, triazole CH), 8.08 (d, J = 7.6 Hz, 1H, Ar-H), 7.87 (d, J = 8.8 Hz, 2H, Ar-H *p*-Cl C₆H₄), 7.84 (d, J = 7.8 Hz, 1H, Ar-H), 7.77 (d, J = 8.0 Hz, 1H, Ar-H), 7.63 (d, J = 8.8 Hz, 2H, Ar-H *p*-Cl C₆H₄), 7.59–7.52 (m, 3H, Ar-H), 7.51–7.43 (m, 3H, Ar-H), 4.53 (s, 2H, S-CH₂). ¹³C NMR (100 MHz, δ ppm DMSO-*d*₆): 160.86, 156.49, 147.32, 143.95, 135.77, 135.37, 135.05, 133.03, 130.06, 129.92, 129.61, 129.51, 126.64, 126.30, 126.18, 122.29, 121.83, 119.71, 26.66. LC-MS (*m/z*) for: C₂₃H₁₆ClN₅OS (exact mass = 445.08); calculated [M + H]⁺: 446.08; found [M + H]⁺: 446.00.

2.1.1.3. 2-(((1-(4-Methoxyphenyl)-1H-1,2,3-triazol-4-yl)methyl)thio)-3-phenylquinazolin-4(3H)-one (8c). Yield: 0.29 g (78%), white solid, m.p: 152–154 °C, *R*_f. 0.58 (hexane : ethyl acetate, 1 : 2, v/v). ¹H NMR (400 MHz, δ ppm DMSO-*d*₆): 8.63 (s, 1H, triazole CH), 8.08 (d, J = 7.6 Hz, 1H, Ar-H), 7.84 (t, J = 7.2 Hz, 1H, Ar-H), 7.76 (d, J = 8.0 Hz, 1H, Ar-H), 7.73 (d, J = 8.6 Hz, 2H, Ar-H *p*-O-CH₃ C₆H₄), 7.63–7.40 (m, 6H, Ar-H), 7.10 (d, J = 8.6 Hz, 2H, Ar-H *p*-O-CH₃ C₆H₄), 4.52 (s, 2H, S-CH₂), 3.80 (s, 3H, O-CH₃). ¹³C NMR (100 MHz, δ ppm DMSO-*d*₆): 160.88, 159.34, 156.59, 147.34, 143.32, 135.80, 135.07, 130.06, 130.01, 129.61, 129.52, 126.66, 126.28, 126.18, 122.22, 121.83, 119.72, 114.94, 55.63, 26.77. LC-MS (*m/z*) for: C₂₄H₁₉N₅O₂S (exact mass = 441.13); calculated [M + H]⁺: 442.13; found [M + H]⁺: 442.10.

2.1.1.4. 2-(((1-(*p*-Tolyl)-1H-1,2,3-triazol-4-yl)methyl)thio)-3-phenylquinazolin-4(3H)-one (8d). Yield: 0.27 g (75%), white solid, m.p: 138–140 °C, *R*_f. 0.57 (hexane : ethyl acetate, 1 : 2, v/v). ¹H NMR (400 MHz, δ ppm DMSO-*d*₆): 8.68 (s, 1H, triazole CH), 8.08 (d, J = 7.2 Hz, 1H, Ar-H), 7.83 (d, J = 8.4 Hz, 1H, Ar-H), 7.76 (d, J = 8.0 Hz, 1H, Ar-H), 7.70 (d, J = 6.0 Hz, 2H, Ar-H *p*-CH₃-C₆H₄), 7.60–7.41 (m, 6H, Ar-H), 7.35 (d, J = 6.0 Hz, 2H, Ar-H *p*-CH₃ C₆H₄), 4.52 (s, 2H, S-CH₂), 2.34 (s, 3H, CH₃). ¹³C NMR (100 MHz, δ ppm DMSO-*d*₆): 160.86, 156.55, 147.31, 138.42, 135.77, 135.05, 134.33, 130.29, 130.04, 129.59, 129.50, 126.64, 126.27, 126.17, 122.15, 122.14, 120.01, 119.70, 26.73, 20.61. LC-MS (*m/z*) for: C₂₄H₁₉N₅OS (exact mass = 425.13); calculated [M + H]⁺: 426.13; found [M + H]⁺: 426.10.



2.1.1.5. *2-(((1-*Phenyl*-1*H*-1,2,3-triazol-4-*yl*)methyl)thio)-3-(*p-tolyl*)quinazolin-4(3*H*)-one (**8e**).* Yield: 0.27 g (75%), white solid, m.p: 139–141 °C, R_f . 0.57 (hexane : ethyl acetate, 1 : 2, v/v). ^1H NMR (400 MHz, δ ppm DMSO- d_6): 8.75 (s, 1H, triazole CH), 8.09 (d, J = 7.7 Hz, 1H, Ar-H), 7.91–7.80 (m, 3H, Ar-H), 7.77 (d, J = 8.0 Hz, 1H, Ar-H), 7.58 (t, J = 7.6 Hz, 2H, Ar-H), 7.51–7.45 (m, 2H, Ar-H), 7.36 (d, J = 8.0 Hz, 2H, Ar-H p -CH₃ C₆H₄), 7.33 (d, J = 8.0 Hz, 2H, Ar-H p -CH₃ C₆H₄), 4.53 (s, 2H, S-CH₂), 2.40 (s, 3H, CH₃). ^{13}C NMR (100 MHz, δ ppm DMSO- d_6): 160.90, 156.83, 147.33, 143.68, 139.75, 136.57, 135.00, 133.14, 130.08, 129.95, 129.20, 128.77, 126.64, 126.26, 126.12, 122.22, 120.13, 119.69, 26.73, 20.90. LC-MS (*m/z*) for: C₂₄H₁₉N₅OS (exact mass = 425.13); calculated [M + H]⁺: 426.13; found [M + H]⁺: 426.10.

2.1.1.6. *2-(((1-*Chlorophenyl*-1*H*-1,2,3-triazol-4-*yl*)methyl)thio)-3-(*p-tolyl*)quinazolin-4(3*H*)-one (**8f**).* Yield: 0.30 g (76%), white solid, m.p: 158–160 °C, R_f . 0.54 (hexane : ethyl acetate, 1 : 2, v/v). ^1H NMR (400 MHz, δ ppm CDCl₃): 8.28 (d, J = 7.2 Hz, 1H, Ar-H), 8.05 (s, 1H, triazole CH), 7.76 (t, J = 6.4 Hz, 1H, Ar-H), 7.69 (d, J = 7.6 Hz, 1H, Ar-H), 7.64 (d, J = 7.8 Hz, 2H, Ar-H p -Cl C₆H₄), 7.48 (d, J = 7.8 Hz, 2H, Ar-H p -Cl C₆H₄), 7.40 (d, J = 8.0 Hz, 1H, Ar-H), 7.33 (d, J = 7.2 Hz, 2H, Ar-H p -CH₃ C₆H₄), 7.19 (d, J = 7.2 Hz, 2H, Ar-H p -CH₃ C₆H₄), 4.59 (s, 2H, S-CH₂), 2.45 (s, 3H, CH₃). ^{13}C NMR (100 MHz, δ ppm CDCl₃): 161.72, 156.88, 147.65, 139.97, 135.34, 134.86, 134.65, 131.04, 129.95, 129.56, 129.54, 127.54, 126.12, 126.02, 125.92, 121.70, 120.96, 120.03, 27.13, 21.37. LC-MS (*m/z*) for: C₂₄H₁₈ClN₅OS (exact mass = 459.09); calculated [M + H]⁺: 460.09; found [M + H]⁺: 460.00.

2.1.1.7. *2-(((1-*Methoxyphenyl*-1*H*-1,2,3-triazol-4-*yl*)methyl)thio)-3-(*p-tolyl*)quinazolin-4(3*H*)-one (**8g**).* Yield: 0.31 g (80%), white solid, m.p: 168–170 °C, R_f . 0.58 (hexane : ethyl acetate, 1 : 2, v/v). ^1H NMR (400 MHz, δ ppm CDCl₃): 8.19 (d, J = 7.4 Hz, 1H, Ar-H), 7.89 (s, 1H, triazole CH), 7.70 (t, J = 7.2 Hz, 1H, Ar-H), 7.60 (d, J = 8.0 Hz, 1H, Ar-H), 7.50 (d, J = 8.8 Hz, 2H, Ar-H p -O-CH₃ C₆H₄), 7.35 (t, J = 7.5 Hz, 1H, Ar-H), 7.25 (d, J = 8.0 Hz, 2H, Ar-H p -CH₃ C₆H₄), 7.11 (d, J = 8.0 Hz, 2H, Ar-H p -CH₃ C₆H₄), 6.91 (d, J = 8.8 Hz, 2H, Ar-H p -O-CH₃ C₆H₄), 4.49 (s, 2H, S-CH₂), 3.77 (s, 3H, O-CH₃), 2.35 (s, 3H, CH₃). ^{13}C NMR (100 MHz, δ ppm CDCl₃): 161.82, 159.88, 157.12, 147.70, 140.43, 134.78, 132.82, 130.58, 130.48, 130.41, 130.15, 128.81, 127.51, 126.01, 125.99, 122.23, 120.01, 114.77, 55.65, 27.27, 21.43. LC-MS (*m/z*) for: C₂₅H₂₁N₅O₂S (exact mass = 455.14); calculated [M + H]⁺: 456.14; found [M + H]⁺: 456.10.

2.1.1.8. *2-(((1-*p-Tolyl*-1*H*-1,2,3-triazol-4-*yl*)methyl)thio)-3-(*p-tolyl*)quinazolin-4(3*H*)-one (**8h**).* Yield: 0.28 g (75%), white solid, m.p: 143–145 °C, R_f . 0.56 (hexane : ethyl acetate, 1 : 2, v/v). ^1H NMR (400 MHz, δ ppm CDCl₃): 8.18 (d, J = 7.2 Hz, 1H, Ar-H), 7.92 (s, 1H, triazole CH), 7.67 (t, J = 6.4 Hz, 1H, Ar-H), 7.59 (d, J = 7.6 Hz, 1H, Ar-H), 7.46 (d, J = 6.8 Hz, 2H, p -CH₃ C₆H₄), 7.34 (t, J = 6.6 Hz, 1H, Ar-H), 7.23 (d, J = 8.0 Hz, 2H, p -CH₃ C₆H₄), 7.14 (d, J = 8.0 Hz, 2H, p -CH₃ C₆H₄), 7.09 (d, J = 6.8 Hz, 2H, p -CH₃ C₆H₄), 4.49 (s, 2H, S-CH₂), 2.34 (s, 3H, CH₃), 2.31 (s, 3H, CH₃). ^{13}C NMR (100 MHz, δ ppm CDCl₃): 161.83, 157.13, 147.70, 140.42, 138.97, 134.80, 134.68, 132.84, 130.47, 130.24, 130.15, 128.81, 127.50, 126.02, 126.00, 121.10, 120.48, 120.01, 27.29, 21.44, 21.12. LC-MS (*m/z*) for: C₂₅H₂₁N₅OS (exact mass = 439.15); calculated [M + H]⁺: 440.15; found [M + H]⁺: 440.20.

2.1.1.9. *2-(((1-*Phenyl*-1*H*-1,2,3-triazol-4-*yl*)methyl)thio)-3-(*m-tolyl*)quinazolin-4(3*H*)-one (**8i**).* Yield: 0.25 g (70%), white solid, m.p: 155–157 °C, R_f . 0.57 (hexane : ethyl acetate, 1 : 2, v/v). ^1H NMR (400 MHz, δ ppm DMSO- d_6): 8.75 (s, 1H, triazole CH), 8.08 (d, J = 7.8 Hz, 1H, Ar-H), 7.87–7.81 (m, 3H, Ar-H), 7.77 (d, J = 8.40 Hz, 1H, Ar-H), 7.56 (t, J = 7.6 Hz, 2H, Ar-H), 7.51–7.40 (m, 3H, Ar-H), 7.35 (d, J = 7.5 Hz, 1H, Ar-H), 7.25 (d, J = 8.0 Hz, 2H, Ar-H), 4.53 (s, 2H, S-CH₂), 2.36 (s, 3H, CH₃). ^{13}C NMR (100 MHz, δ ppm DMSO- d_6): 160.77, 156.56, 147.27, 143.58, 139.15, 136.54, 135.64, 134.96, 130.64, 129.90, 129.66, 129.33, 128.71, 126.58, 126.44, 126.24, 126.09, 122.20, 120.08, 119.66, 26.70, 20.78. LC-MS (*m/z*) for: C₂₄H₁₉N₅OS (exact mass = 425.13); calculated [M + H]⁺: 426.13; found [M + H]⁺: 426.10.

2.1.1.10. *2-(((1-*Chlorophenyl*-1*H*-1,2,3-triazol-4-*yl*)methyl)thio)-3-(*m-tolyl*)quinazolin-4(3*H*)-one (**8j**).* Yield: 0.28 g (72%), white solid, m.p: 177–179 °C, R_f . 0.54 (hexane : ethyl acetate, 1 : 2, v/v). ^1H NMR (400 MHz, δ ppm CDCl₃): 8.19 (d, J = 7.7 Hz, 1H, Ar-H), 7.96 (s, 1H, triazole CH), 7.70 (t, J = 7.3 Hz, 1H, Ar-H), 7.60 (d, J = 8.0 Hz, 1H, Ar-H), 7.55 (d, J = 8.4 Hz, 2H, Ar-H p -Cl C₆H₄), 7.39 (d, J = 8.4 Hz, 2H, Ar-H p -Cl C₆H₄), 7.35 (d, J = 7.2 Hz, 1H, Ar-H), 7.32 (d, J = 8.0 Hz, 1H, Ar-H), 7.25 (d, J = 7.6 Hz, 1H, Ar-H), 7.02 (d, J = 6.4 Hz, 2H, Ar-H), 4.49 (s, 2H, S-CH₂), 2.33 (s, 3H, CH₃). ^{13}C NMR (100 MHz, δ ppm CDCl₃): 161.77, 157.03, 147.66, 145.10, 140.48, 135.41, 134.83, 134.58, 132.79, 130.49, 130.14, 129.93, 128.79, 128.06, 127.53, 126.08, 125.94, 121.69, 120.93, 120.01, 27.16, 21.44. LC-MS (*m/z*) for: C₂₄H₁₈ClN₅OS (exact mass = 459.09); calculated [M + H]⁺: 460.09; found [M + H]⁺: 460.10.

2.1.1.11. *2-(((1-*Methoxyphenyl*-1*H*-1,2,3-triazol-4-*yl*)methyl)thio)-3-(*m-tolyl*)quinazolin-4(3*H*)-one (**8k**).* Yield: 0.28 g (73%), white solid, m.p: 186–188 °C, R_f . 0.58 (hexane : ethyl acetate, 1 : 2, v/v). ^1H NMR (400 MHz, δ ppm CDCl₃): 8.28 (d, J = 5.6 Hz, 1H, Ar-H), 8.00 (s, 1H, triazole CH), 7.78 (s, 1H, Ar-H), 7.71 (s, 1H, Ar-H), 7.58 (d, J = 5.8 Hz, 2H, Ar-H p -OCH₃ C₆H₄), 7.43 (d, J = 6.4 Hz, 2H, Ar-H), 7.34 (s, 1H, Ar-H), 7.12 (s, 2H, Ar-H), 6.99 (d, J = 5.8 Hz, 2H, Ar-H p -OCH₃ C₆H₄), 4.61 (s, 2H, S-CH₂), 3.86 (s, 3H, OCH₃), 2.42 (s, 3H, CH₃). ^{13}C NMR (100 MHz, δ ppm CDCl₃): 161.76, 159.87, 157.00, 147.69, 139.93, 135.39, 134.82, 131.00, 130.38, 129.55, 129.54, 129.27, 127.47, 126.03, 126.01, 125.88, 125.34, 122.21, 120.00, 114.76, 55.65, 27.31, 21.38. LC-MS (*m/z*) for: C₂₅H₂₁N₅O₂S (exact mass = 455.14); calculated [M + H]⁺: 456.14; found [M + H]⁺: 456.10.

2.1.1.12. *2-(((1-*p-Tolyl*-1*H*-1,2,3-triazol-4-*yl*)methyl)thio)-3-(*m-tolyl*)quinazolin-4(3*H*)-one (**8l**).* Yield: 0.26 g (70%), white solid, m.p: 158–160 °C, R_f . 0.56 (hexane : ethyl acetate, 1 : 2, v/v). ^1H NMR (400 MHz, δ ppm CDCl₃): 8.17 (s, 1H, Ar-H), 7.93 (s, 1H, triazole CH), 7.67 (s, 1H, Ar-H), 7.60 (s, 1H, Ar-H), 7.45 (s, 2H, Ar-H p -CH₃ C₆H₄), 7.32 (s, 2H, Ar-H), 7.19 (s, 3H, Ar-H), 7.02 (s, 2H, Ar-H p -CH₃ C₆H₄), 4.48 (s, 2H, S-CH₂), 2.31 (s, 6H, 2CH₃). ^{13}C NMR (100 MHz, δ ppm CDCl₃): 161.78, 157.01, 147.71, 139.93, 138.93, 135.49, 135.41, 135.34, 134.82, 134.72, 130.99, 130.24, 129.56, 129.55, 127.47, 126.19, 126.04, 125.99, 120.47, 120.01, 27.30, 21.38, 21.12. LC-MS (*m/z*) for: C₂₅H₂₁N₅OS (exact mass = 439.15); calculated [M + H]⁺: 440.15; found [M + H]⁺: 440.00.

2.1.1.13. *2-(((1-*Phenyl*-1*H*-1,2,3-triazol-4-*yl*)methyl)thio)-3-ethyl quinazolin-4(3*H*)-one (**8m**).* Yield: 0.21 g (67%), white solid,



m.p: 120–122 °C, R_f 0.51 (hexane : ethyl acetate, 1 : 2, v/v). ^1H NMR (400 MHz, δ ppm DMSO- d_6): 8.82 (s, 1H, triazole CH), 8.08 (d, J = 7.7 Hz, 1H, Ar-H), 7.86 (d, J = 7.0 Hz, 1H, Ar-H), 7.68–7.60 (m, 4H, Ar-H), 7.48 (t, J = 7.2 Hz, 1H, Ar-H), 7.30 (d, J = 8.4 Hz, 2H, Ar-H), 4.70 (s, 2H, S-CH₂), 4.08 (q, J = 6.8 Hz, 2H, N-CH₂), 1.16 (t, J = 6.8 Hz, 3H, CH₃). ^{13}C NMR (100 MHz, δ ppm DMSO- d_6): 161.29, 155.65, 147.31, 143.74, 138.96, 135.66, 134.42, 130.33, 127.32, 125.95, 125.83, 123.12, 121.58, 119.85, 39.85, 26.68, 13.29.

2.1.1.14. *2-(((1-(4-Chlorophenyl)-1H-1,2,3-triazol-4-yl)methyl)thio)-3-ethyl quinazolin-4(3H)-one (8n).* Yield: 0.23 g (69%), white solid, m.p: 132–134 °C, R_f 0.53 (hexane : ethyl acetate, 1 : 2, v/v). ^1H NMR (400 MHz, δ ppm CDCl₃): 8.15 (dd, J = 8.0, 1.1 Hz, 1H, Ar-H), 7.99 (s, 1H, triazole CH), 7.69–7.61 (m, 1H, Ar-H), 7.55 (d, J = 8.8 Hz, 2H, Ar-H *p*-Cl C₆H₄), 7.52 (s, 1H, Ar-H), 7.38 (d, J = 8.8 Hz, 2H, Ar-H *p*-Cl C₆H₄), 7.35–7.30 (m, 1H, Ar-H), 4.63 (s, 2H, S-CH₂), 4.10 (q, J = 7.1 Hz, 2H, N-CH₂), 1.29 (t, J = 7.1 Hz, 3H, CH₃). ^{13}C NMR (100 MHz, δ ppm CDCl₃): 161.32, 155.62, 147.21, 135.45, 134.59, 134.49, 132.99, 129.93, 127.19, 125.95, 125.63, 124.92, 121.71, 119.56, 39.87, 26.55, 13.27. LC-MS (*m/z*) for: C₁₉H₁₆ClN₅OS (exact mass = 397.08); calculated [M + H]⁺: 398.08; found [M + H]⁺: 398.00.

2.1.1.15. *2-(((1-(4-Methoxyphenyl)-1H-1,2,3-triazol-4-yl)methyl)thio)-3-ethyl quinazolin-4(3H)-one (8o).* Yield: 0.23 g (69%), white solid, m.p: 142–144 °C, R_f 0.49 (hexane : ethyl acetate, 1 : 2, v/v). ^1H NMR (400 MHz, δ ppm CDCl₃): 8.15 (d, J = 7.6 Hz, 1H, Ar-H), 7.92 (s, 1H, triazole CH), 7.64 (t, J = 7.2 Hz, 1H, Ar-H), 7.49 (d, J = 8.5 Hz, 2H, Ar-H *p*-OCH₃ C₆H₄), 7.32 (t, J = 7.4 Hz, 1H, Ar-H), 7.21 (d, J = 8.0 Hz, 1H, Ar-H), 6.90 (d, J = 8.5 Hz, 2H, Ar-H *p*-OCH₃ C₆H₄), 4.62 (s, 2H, S-CH₂), 4.10 (q, J = 6.8 Hz, 2H, N-CH₂), 3.76 (s, 3H, OCH₃), 1.28 (t, J = 6.8 Hz, 3H, CH₃). ^{13}C NMR (100 MHz, δ ppm CDCl₃): 161.38, 159.85, 155.66, 149.57, 147.31, 134.42, 128.64, 127.13, 125.85, 123.33, 122.22, 119.56, 115.26, 114.75, 55.63, 39.83, 26.68, 13.26. LC-MS (*m/z*) for: C₂₀H₁₉N₅O₂S (exact mass = 393.13); calculated [M + H]⁺: 394.13; found [M + H]⁺: 394.00.

2.1.1.16. *2-(((1-(*p*-Tolyl)-1H-1,2,3-triazol-4-yl)methyl)thio)-3-ethylquinazolin-4(3H)-one (8p).* Yield: 0.22 g (68%), white solid, m.p: 125–127 °C, R_f 0.52 (hexane : ethyl acetate, 1 : 2, v/v). ^1H NMR (400 MHz, δ ppm CDCl₃): 8.14 (dd, J = 7.9, 0.9 Hz, 1H, Ar-H), 7.95 (s, 1H, triazole CH), 7.66–7.59 (m, 1H, Ar-H), 7.52 (d, J = 8.0 Hz, 1H, Ar-H), 7.46 (d, J = 8.4 Hz, 2H, Ar-H *p*-CH₃ C₆H₄), 7.34–7.27 (m, 1H, Ar-H), 7.19 (d, J = 8.4 Hz, 2H, Ar-H *p*-CH₃ C₆H₄), 4.62 (s, 2H, S-CH₂), 4.09 (q, J = 7.1 Hz, 2H, N-CH₂), 2.31 (s, 3H, benzylic CH₃), 1.28 (t, J = 7.1 Hz, 3H, CH₃). ^{13}C NMR (100 MHz, δ ppm CDCl₃): 161.37, 155.65, 147.31, 144.63, 138.97, 134.66, 134.42, 130.23, 127.12, 125.84, 125.74, 121.11, 120.48, 119.56, 39.82, 26.66, 21.10, 13.26. LC-MS (*m/z*) for: C₂₀H₁₉N₅OS (exact mass = 377.13); calculated [M + H]⁺: 378.13; found [M + H]⁺: 378.10.

2.1.1.17. *2-(((1-Phenyl-1H-1,2,3-triazol-4-yl)methyl)thio)-3-allyl quinazolin-4(3H)-one (8q).* Yield: 0.21 g (66%), white solid, m.p: 124–126 °C, R_f 0.50 (hexane : ethyl acetate, 1 : 2, v/v). ^1H NMR (400 MHz, δ ppm DMSO- d_6): 8.70 (s, 1H, triazole CH), 8.06 (d, J = 7.8 Hz, 1H, Ar-H), 7.96 (d, J = 6.8 Hz, 2H, Ar-H), 7.74 (t, J = 7.5 Hz, 1H, Ar-H), 7.61–7.50 (m, 3H, Ar-H), 7.45 (t, J = 7.5 Hz, 1H, Ar-H), 7.35 (d, J = 8.1 Hz, 1H, Ar-H), 5.96–5.82 (m, 1H, =CH), 5.21 (d, J = 10.0 Hz, 1H, =CH₂), 5.11 (d, J = 16.0 Hz, 1H, =CH₂), 4.90 (s, 2H, S-CH₂), 4.74 (d, J = 4.0 Hz, 2H, N-CH₂); ^{13}C

NMR (100 MHz, δ ppm DMSO- d_6): 160.21, 154.96, 146.46, 138.97, 134.94, 131.63, 131.26, 129.31, 126.96, 126.54, 126.36, 126.02, 125.71, 120.62, 118.74, 117.62, 45.96, 26.80.

2.1.1.18. *2-(((1-(4-Chlorophenyl)-1H-1,2,3-triazol-4-yl)methyl)thio)-3-allyl quinazolin-4(3H)-one (8r).* Yield: 0.25 g (71%), white solid, m.p: 137–139 °C, R_f 0.54 (hexane : ethyl acetate, 1 : 2, v/v). ^1H NMR (400 MHz, δ ppm CDCl₃): 8.15 (d, J = 7.6 Hz, 1H, Ar-H), 7.97 (s, 1H, triazole CH), 7.65 (t, J = 7.4 Hz, 1H, Ar-H), 7.54 (d, J = 8.4 Hz, 2H, Ar-H *p*-Cl C₆H₄), 7.52 (s, 1H, Ar-H), 7.38 (d, J = 8.4 Hz, 2H, Ar-H *p*-Cl C₆H₄), 7.33 (d, J = 7.6 Hz, 1H, Ar-H), 5.91–5.76 (m, 1H, =CH), 5.20 (d, J = 12.0 Hz, 1H, =CH₂), 5.17 (d, J = 6.0 Hz, 1H, =CH₂), 4.67 (d, J = 5.1 Hz, 2H, N-CH₂), 4.63 (s, 2H, S-CH₂). ^{13}C NMR (100 MHz, δ ppm CDCl₃): 161.35, 155.75, 147.26, 144.87, 135.41, 134.63, 130.26, 129.94, 127.32, 126.25, 126.04, 125.75, 121.70, 121.07, 119.47, 118.59, 46.39, 26.72. LC-MS (*m/z*) for: C₂₀H₁₆ClN₅OS (exact mass = 409.08); calculated [M + H]⁺: 410.08; found [M + H]⁺: 410.00.

2.1.1.19. *2-(((1-(4-Methoxyphenyl)-1H-1,2,3-triazol-4-yl)methyl)thio)-3-allyl quinazolin-4(3H)-one (8s).* Yield: 0.25 g (72%), white solid, m.p: 148–150 °C, R_f 0.48 (hexane : ethyl acetate, 1 : 2, v/v). ^1H NMR (400 MHz, δ ppm DMSO- d_6): 8.70 (s, 1H, triazole CH), 8.08 (s, 1H, Ar-H), 7.81–7.70 (m, 4H, Ar-H), 7.48 (s, 1H, Ar-H), 7.12 (s, 2H, Ar-H), 5.95–5.85 (m, 1H, =CH), 5.16 (d, J = 16.0 Hz, 1H, =CH₂), 5.12 (d, J = 8.0 Hz, 1H, =CH₂), 4.68 (s, 4H, N-CH₂ & S-CH₂), 3.81 (s, 3H, OCH₃). ^{13}C NMR (100 MHz, δ ppm DMSO- d_6): 161.63, 159.95, 154.98, 149.57, 146.73, 134.82, 131.24, 128.64, 126.89, 126.13, 125.74, 122.25, 120.22, 119.28, 117.56, 114.69, 55.37, 45.93, 26.70. LC-MS (*m/z*) for: C₂₁H₁₉N₅O₂S (exact mass = 405.13); calculated [M + H]⁺: 406.13; found [M + H]⁺: 406.10.

2.1.1.20. *2-(((1-(*p*-Tolyl)-1H-1,2,3-triazol-4-yl)methyl)thio)-3-allyl quinazolin-4(3H)-one (8t).* Yield: 0.23 g (69%), white solid, m.p: 130–132 °C, R_f 0.53 (hexane : ethyl acetate, 1 : 2, v/v). ^1H NMR (400 MHz, δ ppm CDCl₃): 8.15 (d, J = 7.6 Hz, 1H, Ar-H), 7.94 (s, 1H, triazole CH), 7.64 (t, J = 7.4 Hz, 1H, Ar-H), 7.53 (d, J = 8.0 Hz, 1H, Ar-H), 7.46 (d, J = 8.4 Hz, 2H, Ar-H *p*-CH₃ C₆H₄), 7.32 (t, J = 7.6 Hz, 1H, Ar-H), 7.18 (d, J = 8.4 Hz, 2H, Ar-H *p*-CH₃ C₆H₄), 5.94–5.73 (m, 1H, =CH), 5.20 (d, J = 14.0 Hz, 1H, =CH₂), 5.16 (d, J = 6.8 Hz, 1H, =CH₂), 4.67 (d, J = 5.2 Hz, 2H, N-CH₂), 4.62 (s, 2H, S-CH₂), 2.31 (s, 3H, CH₃). ^{13}C NMR (100 MHz, δ ppm CDCl₃): 161.38, 155.87, 147.30, 144.50, 138.96, 134.67, 134.58, 130.54, 130.23, 127.27, 125.96, 125.81, 121.12, 120.47, 119.46, 118.78, 46.37, 26.85, 21.10. LC-MS (*m/z*) for: C₂₁H₁₉N₅OS (exact mass = 389.13); calculated [M + H]⁺: 390.13; found [M + H]⁺: 390.10.

2.2. Biology

2.2.1. Cell viability assay. The viability of new compounds **8a–t** was evaluated using the MCF-10A normal human mammary gland epithelial cell line. The cell viability of compounds **8a–t** was examined using the MTT assay³⁶ after four days of incubation with MCF-10A cells. For more details, see Appendix A (ESI file).†

2.2.2. Antiproliferative assay. The MTT assay was used to explore the antiproliferative efficacy of **8a–t** against the four human cancer cell lines, using Erlotinib as a control.³⁷ The median inhibitory concentration (IC₅₀) and GI₅₀ (mean IC₅₀) for



the four cancer cell lines were calculated. Appendix A† contains more details.

2.2.3. EGFR inhibitory assay. The EGFR-TK assay was employed³⁸ to evaluate the inhibitory efficacy of the most potent antiproliferative derivatives **8f**, **8g**, **8h**, **8j**, and **8l** against EGFR. See Appendix A† for more information.

2.2.4. BRAF^{V600E} inhibitory assay. An *in vitro* study evaluated the anti-BRAF^{V600E} efficacy of compounds **8f**, **8g**, **8h**, **8j**, and **8l** according to reported procedures.³⁹ See Appendix A† for more details.

2.2.5. Apoptotic markers assays. Compounds **8g** and **8h** were evaluated as caspase-3, 8 and Bax activators and as down-regulator of the anti-apoptotic protein Bcl2 against the MCF-7 breast cancer cell line.⁴⁰ Appendix A† contains more details.

2.2.6. Cell cycle analysis and apoptosis detection. The impact of compound **8g** on cell cycle progression and apoptosis induction was examined in A-549 cells. A lung cancer (A-549) cell line was subjected to treatment for 24 hours with an IC₅₀

concentration of **8g**. We stained the cell line with PI/annexin V and performed flow cytometry using a BD FACS Caliber.⁴¹ Refer to Appendix A† for more details.


2.3. Docking study

Molecular docking simulations within EGFR (PDB ID: 1M17)⁴² and BRAF^{V600E} (PDB ID: 4RZV).⁴³ Were validated with a redocking test, whereby the test proteins' structures had remained fixed while the co-crystallized ligands (Erlotinib for EGFR and Vemurafenib for BRAF^{V600E}) were redocked into their crystal-binding pocket. See Appendix A† for more details.

3. Results and discussion

3.1. Chemistry

Scheme 1 depicts the synthetic methods for the novel target hybrids (**8a–t**). We refluxed anthranilic acid (**1**) in ethanol with



Scheme 1 Synthesis of the new target compounds **8a–t**. Reagents and conditions: (a) TEA, ethanol, reflux (8–12 h), (b) K₂CO₃, DMF, stirring (24 h), (c) 1-NaNO₂, HCl, 2-Na₃N (d) sodium ascorbate, CuSO₄·5H₂O, THF, reflux (24–48 h).



isothiocyanate derivatives (**2a–e**) for 8 h. After the reaction was complete (as determined by TLC), the resulting white precipitate was filtered and recrystallized from an ethanol/dioxane mixture (1 : 1), yielding quinazoline-4-ones (**3a–e**) in 90–95% yields.⁴⁴ The quinazoline derivatives (**3a–e**) were then alkylated with propargyl bromide (**4**) in the presence of anhydrous K_2CO_3 by stirring in DMF, yielding S-propargyl derivatives (**5a–e**) in 70–83% yields that were purified by ethanol recrystallization.⁴⁵

FTIR spectrum of **5c**, as an example, revealed the appearance of the characteristic peak of $\equiv C-H$ stretching at ν 3245 cm^{-1} , 3066 ($=C-H$ stretching), 2968, 2928 (sp^3C-H stretching), 2116 ($C\equiv C$) and 1687 ($C=O$). The diazotization of aniline derivatives (**6a–d**) with $NaNO_2/HCl$ at 0–5 °C, followed by the addition of sodium azide, resulted in the formation of the corresponding aromatic azides (**7a–d**) with a yield of 70–75%.⁴⁶ The FTIR spectrum of **7c** confirmed the appearance of the characteristic peak of the azide group at 2109 cm^{-1} .

1,3-Dipolar cycloaddition reactions between propargyl derivatives (**5a–e**) and aromatic azides (**7a–d**) were carried out by refluxing in THF in the presence of $CuSO_4 \cdot 5H_2O$ /sodium ascorbate as a catalyst, yielding 1,4-disubstituted 1,2,3-triazoles (**8a–t**) in good yields (86–90%). The structures of **8a–t**


were elucidated using 1H NMR, ^{13}C NMR spectroscopy, and LC-MS. The 1H NMR spectra of compound **8g**, as an example, confirmed the presence of three characteristic singlet signals in the aliphatic range: first one at δ 2.36 (s, 3H, CH_3), second one at δ 3.77 (s, 3H, $O-CH_3$) and third one at δ 4.49 (s, 2H, $S-CH_2$). Additionally, the spectrum revealed another characteristic singlet signal in the aromatic range at δ 7.89 of the triazole CH (s, 1H, triazole CH).

Also, the spectrum revealed two pairs of doublets of the aromatic ring's *p*-disubstituted patterns and extra signals for the aromatic protons in the quinazoline moiety. The ^{13}C NMR spectrum of **8g** indicated the presence of peaks of methoxy, methylene, and methyl groups at δ 55.65, δ 27.27, and δ 21.43 ppm, respectively. The ^{13}C NMR spectrum of **8g** also indicated a peak at δ 161.82 ppm of the amidic carbonyl group. LC-MS spectrum of compound **8g** ($C_{25}H_{21}N_5O_2S$, M. Wt = 455.14) showed a signal at 456.10 m/z [M + H]⁺.

3.2. Biology

3.2.1. Cell viability assay. We evaluated the viability of new compounds **8a–t** using the MCF-10A normal human mammary

Table 1 Cell viability % and IC_{50} values of compounds **8a–t** against four cancer cell lines using MTT assay



Comp.	Cell viability %	R_1	R_2	Antiproliferative activity $IC_{50} \pm SEM$ (nM)				
				A-549	MCF-7	Panc-1	HT-29	Average (GI_{50})
8a	89	Phenyl	H	61 ± 5	56 ± 5	64 ± 5	64 ± 5	61
8b	90	Phenyl	Cl	40 ± 3	36 ± 3	42 ± 3	44 ± 3	41
8c	86	Phenyl	OMe	47 ± 3	42 ± 3	49 ± 3	49 ± 3	47
8d	89	Phenyl	Me	53 ± 4	48 ± 4	56 ± 4	56 ± 4	53
8e	90	<i>p</i> -Tolyl	H	88 ± 8	85 ± 8	92 ± 8	92 ± 8	89
8f	87	<i>p</i> -Tolyl	Cl	37 ± 3	34 ± 3	38 ± 3	39 ± 3	37
8g	88	<i>p</i> -Tolyl	OMe	22 ± 1	20 ± 1	24 ± 1	24 ± 1	22
8h	92	<i>p</i> -Tolyl	Me	25 ± 1	22 ± 1	26 ± 1	27 ± 1	25
8i	90	<i>m</i> -Tolyl	H	65 ± 5	59 ± 5	68 ± 6	68 ± 6	65
8j	87	<i>m</i> -Tolyl	Cl	29 ± 2	26 ± 2	31 ± 2	30 ± 2	29
8k	85	<i>m</i> -Tolyl	OMe	42 ± 3	39 ± 3	46 ± 3	45 ± 3	43
8l	87	<i>m</i> -Tolyl	Me	33 ± 2	29 ± 2	36 ± 2	35 ± 2	33
8m	90	Ethyl	H	72 ± 6	68 ± 6	74 ± 6	74 ± 6	72
8n	92	Ethyl	Cl	75 ± 6	71 ± 6	78 ± 6	79 ± 6	76
8o	89	Ethyl	OMe	69 ± 5	63 ± 5	74 ± 6	74 ± 6	70
8p	86	Ethyl	Me	82 ± 7	77 ± 7	84 ± 7	85 ± 7	82
8q	87	Allyl	H	93 ± 8	89 ± 8	96 ± 8	96 ± 8	94
8r	90	Allyl	Cl	79 ± 6	75 ± 6	81 ± 7	84 ± 7	80
8s	91	Allyl	OMe	57 ± 5	53 ± 4	59 ± 5	59 ± 5	57
8t	90	Allyl	Me	84 ± 7	80 ± 7	87 ± 7	87 ± 7	85
Erlotinib	ND	—	—	30 ± 3	40 ± 3	30 ± 3	30 ± 3	33

gland epithelial cell line. The cell viability of compounds **8a–t** was examined using the MTT assay³⁶ after four days of incubation with MCF-10A cells. Table 1 indicates that none of the compounds analyzed exhibited cytotoxicity, with all hybrids maintaining above 84% cell viability at a concentration of 50 μ M.

3.2.2. Antiproliferative assay. The MTT assay was used to test the antiproliferative efficacy of hybrids **8a–t** against four human cancer cell lines: colon cancer (HT-29), pancreatic cancer (Panc-1), lung cancer (A-549), and breast cancer (MCF-7), using Erlotinib as a control.^{37,47} Table 1 presents the median inhibitory concentration (IC₅₀) and GI₅₀ (mean IC₅₀) for the four cancer cell lines.

Compared to Erlotinib, which had a GI₅₀ of 33 nM, compounds **8a–t** had substantial antiproliferative action, with GI₅₀ values ranging from 22 nM to 94 nM *versus* the four cancer cell lines evaluated. In that order, the most potent derivatives were **8f**, **8g**, **8h**, **8j**, and **8l**, with GI₅₀ values of 37, 22, 25, 29, and 33 nM. This means that **8g**, **8h**, and **8j** were stronger than Erlotinib (GI₅₀ = 33 nM). The most potent of the newly synthesized hybrids **8a–t** was compound **8g** (R₁ = *p*-tolyl, R₂ = OMe), which had a GI₅₀ value of 22 nM, which is 1.5 times stronger than the standard Erlotinib (GI₅₀ = 33 nM). The nature of the aryl/alkyl substituents at position 3 of the quinazoline moiety appears to be critical for the **8a–t** hybrids' antiproliferative activity. The GI₅₀ values of compounds **8h** (R₁ = *p*-tolyl, R₂ = Me) and **8j** (R₁ = *m*-tolyl, R₂ = Cl) were 25 nM and 29 nM, respectively. These values were lower than compound **8g**'s (GI₅₀ = 22 nM) but higher than the reference erlotinib. Also, compounds **8k** (R₁ = *m*-tolyl, R₂ = OMe) and **8l** (R₁ = *m*-tolyl, R₂ = Me) had GI₅₀ values of 43 and 33 nM, respectively. These were less potent than compounds **8g**, **8h**, and **8j**, but **8l** performed similarly to erlotinib, while **8k** is less effective than erlotinib. These data demonstrated that the *p*-tolyl group at position 3 of the quinazoline moiety is more tolerated for antiproliferative action than the *m*-tolyl one. Additionally, the GI₅₀ values for compounds **8c** (R₁ = phenyl, R₂ = OMe), **8o** (R₁ = ethyl, R₂ = OMe), and **8s** (R₁ = allyl, R₂ = OMe) were 47, 70, and 57 nM, respectively. These values are lower than those for compound **8g** (R₁ = *p*-tolyl, R₂ = OMe) and even Erlotinib. The results highlighted the importance of the substitution pattern at position three of the quinazoline moiety in antiproliferative activity, with efficacy increasing in the following order: *p*-tolyl > *m*-tolyl > phenyl > allyl > ethyl.

Also, the pattern of substitution at the fourth position of the phenyl group within the 1,2,3-triazole moiety (R₂) may significantly impact how effectively **8a–t** hybrids inhibit cell proliferation. The GI₅₀ values for compounds **8e** (R₁ = *p*-tolyl, R₂ = H), **8f** (R₁ = *p*-tolyl, R₂ = Cl), and **8h** (R₁ = *p*-tolyl, R₂ = Me) were 89, 37, and 25 nM, respectively, demonstrating lower potency than **8g** (R₁ = *p*-tolyl, R₂ = OMe), which exhibited a GI₅₀ value of 22 nM. The results show that the antiproliferative activity of these hybrids is affected by the pattern of substitutions at the fourth position of the phenyl group in the 1,2,3-triazole moiety. The activity decreases from OMe to Me to Cl, with compound **8e**, the unsubstituted derivative (R₂ = H), having the least potency.

It is 4-fold less potent than compound **8g**, the methoxy derivative.

Another significant feature is that all tested compounds exhibited heightened sensitivity to the breast cancer (MCF-7) cell line compared to the other cell lines investigated. For example, compound **8g** (R₁ = *p*-tolyl, R₂ = OMe) had the most activity, with IC₅₀ values of 22, 20, 24, and 24 nM against lung cancer-A-549, breast cancer-MCF-7, pancreatic cancer-Panc-1 pancreatic, and colon cancer-HT-29 cancer cell lines, respectively. It was more effective than erlotinib against all four cancer cell lines and twice as effective against the MCF-7 breast cancer cell line. The same rule applies to all derivatives, regardless of the characteristics of (R₂) or how the quinazoline moiety is substituted at position 3.

3.2.3. EGFR inhibitory assay. We employed the EGFR-TK assay^{38,48} to evaluate the inhibitory efficacy of the most potent antiproliferative derivatives **8f**, **8g**, **8h**, **8j**, and **8l** against EGFR, and presented the results in Table 2. The results of this test are the same as the results of the antiproliferative test, which found that compounds **8g** (R₁ = *p*-tolyl, R₂ = OMe), **8h** (R₁ = *p*-tolyl, R₂ = Me), and **8j** (R₁ = *m*-tolyl, R₂ = Cl) were the best anti-proliferative agent. With IC₅₀ values of 68 \pm 4 nM, 74 \pm 5 nM, and 78 \pm 5 nM, these compounds were the most effective EGFR inhibitor derivatives. They worked better than the standard drug Erlotinib (IC₅₀ = 80 \pm 5 nM). Compounds **8f** (R₁ = *p*-tolyl, R₂ = Cl) and **8l** (R₁ = *m*-tolyl, R₂ = Me) had strong anti-EGFR activity, with IC₅₀ values of 89 \pm 5 nM and 83 \pm 5 nM, respectively. These values are the same as Erlotinib's IC₅₀ value of 80 nM. These results indicate that compounds **8g**, **8h**, and **8j** exhibit substantial EGFR inhibitory activity and may serve as potential antiproliferative agents.

3.2.4. BRAF^{V600E} inhibitory assay. An *in vitro* study evaluated the anti-BRAF^{V600E} efficacy of compounds **8f**, **8g**, **8h**, **8j**, and **8l**.³⁹ The enzyme test showed that the five hybrids tested strongly blocked BRAF^{V600E}, with IC₅₀ values ranging from 47 to 69 nM, as shown in Table 2. In all cases, the IC₅₀ of the analyzed compounds exceeds that of the reference Vemurafenib (IC₅₀ = 30 nM), indicating reduced potency. Compounds **8g**, **8h**, and **8j** demonstrated the highest inhibitory efficacy against BRAF^{V600E} (IC₅₀ = 47, 55, and 61 nM, respectively), and demonstrated significant inhibition of cancer cell growth (GI₅₀ = 22, 25, and 33 nM, respectively). As a result, compounds **8g**, **8h**, and **8j** are potential antiproliferative agents that operate as dual inhibitors of EGFR and BRAF^{V600E}.

Table 2 IC₅₀ values of compounds **8f**, **8g**, **8h**, **8j**, and **8l** against EGFR and BRAF^{V600E} against MCF-7 cancer cell line

Compound	EGFR inhibition IC ₅₀ \pm SEM (nM)	BRAF ^{V600E} inhibition IC ₅₀ \pm SEM (nM)
8f	89 \pm 5	69 \pm 5
8g	68 \pm 4	47 \pm 3
8h	74 \pm 5	55 \pm 5
8j	78 \pm 5	61 \pm 5
8l	83 \pm 5	64 \pm 5
Erlotinib	80 \pm 5	60 \pm 5
Vemurafenib	ND	30 \pm 3



3.2.5. Assay for the activation of apoptotic markers. Apoptosis, or programmed cell death, involves numerous biochemical and morphological mechanisms.^{49,50} Antiapoptotic proteins, like Bcl-2 and Bc-W, coexist with proapoptotic proteins such as Bad and Bax.^{51,52} Pro-apoptotic proteins promote cytochrome c release, while anti-apoptotic proteins regulate apoptosis by preventing cytochrome c release. The outer mitochondrial membrane becomes permeable when the concentration of proapoptotic proteins surpasses that of antiapoptotic proteins, initiating a cascade of events. The release of cytochrome c activates caspase-3 and caspase-9. Caspase-3 initiates apoptosis by targeting multiple essential proteins that are required for cellular function.^{53,54}

We further investigated the ability of compounds **8g** and **8h**, the most effective in all *in vitro* studies, to activate apoptotic markers.

3.2.5.1. Caspase-3 activation assay. Compounds **8g** and **8h** were evaluated as caspase-3 activators against the MCF-7 breast cancer cell line,⁴⁰ with results presented in Table 3. It was found that derivatives **8g** and **8h** had significantly higher levels of caspase-3 protein (695 ± 5 and 650 ± 5 pg mL⁻¹, respectively) compared to the standard substance staurosporine (503 ± 4 pg mL⁻¹). The compounds **8g** and **8h** increased the concentration of caspase-3 protein in the MCF-7 cancer cell line, showing levels that were 11 and 10 times higher than the untreated control and higher than staurosporine. These data indicate that apoptosis may play a role in the antiproliferative effects of the investigated compounds, possibly due to caspase-3 upregulation.

3.2.5.2. Assay for caspase-8, Bax and Bcl-2 levels. We further examined the effects of compounds **8g** and **8h** on caspase-8, Bax, and the anti-apoptotic Bcl2 levels in the MCF-7 cancer cell line, using staurosporine as a reference.⁴⁰ Table 4 displays the findings. The results indicated that **8g** and **8h** markedly elevated Bax and caspase-8 levels in comparison to




Fig. 5 Results for cell cycle analysis of **8g** in A-549 cell line.

staurosporine. Compound **8g** had the most overexpression of caspase-8 (2.60 ng mL⁻¹), followed by compound **8h** (2.10 ng mL⁻¹) and staurosporine as a control (1.80 ng mL⁻¹). Furthermore, **8g** and **8h** demonstrated greater Bax induction (315 and 295 pg mL⁻¹, respectively) relative to staurosporine (280 pg mL⁻¹), exhibiting a 39-fold and 37-fold increase compared to untreated control MCF-7 cancer cells.

Finally, compound **8g** caused a marked drop in the concentration of Bcl-2 protein (0.70 ng mL⁻¹), followed by




Fig. 6 The apoptosis induction results of **8g**.

Table 3 Caspase-3 activation of compounds **8g** and **8h** against MCF-7 cancer cell line

Compound number	Caspase-3	
	Conc. (pg mL ⁻¹)	Fold change
8g	695 ± 5	11
8h	650 ± 5	10
Staurosporine	503 ± 4	8
Control	63	1

Table 4 Caspase-8, Bax, and Bcl-2 levels of compounds **8g** and **8h** in cancer MCF-7 cell line

Compound number	Caspase-8		Bax		Bcl-2	
	Conc. (ng mL ⁻¹)	Fold change	Conc. (pg mL ⁻¹)	Fold change	Conc. (ng mL ⁻¹)	Fold reduction
8g	2.60 ± 0.20	28	315 ± 9	39	0.70	7
8h	2.10 ± 0.20	23	295 ± 9	37	0.90	6
Staurosporine	1.80 ± 0.10	20	280 ± 7	35	1.10	5
Control	0.09	1	8	1	5	1






Fig. 7 Cell cycle analysis and apoptosis induction results of **8g**.

compound **8h** (0.90 ng mL⁻¹) in the MCF-7 cell line compared to staurosporine (1.10 ng mL⁻¹). The apoptosis assay showed that compounds **8g** and **8h** have dual inhibitory effects against EGFR and BRAF^{V600E}, showing strong apoptotic antiproliferative effect.

3.2.6. Cell cycle analysis and apoptosis assays

3.2.6.1. Cell cycle analysis. The effects of **8g** on cell cycle progression and apoptosis induction in A-549 cells were examined. A lung cancer (A-549) cell line was subjected to treatment for 24 hours with an IC₅₀ concentration of **8g**. We stained the cell line with PI/annexin V and performed flow cytometry using a BD FACS Caliber.⁴¹ The results (Fig. 5) showed that A-549 cells treated with compound **8g** had a significant accumulation of 86% in the G0/G1 phase after 24 hours of incubation. This means a cell cycle arrest at the G1 transition.

3.2.6.2. Apoptosis induction assay. A-549 cells were stained with annexin V/PI, cultured for 24 hours, and analyzed them to

Table 5 Docking scores (S; kcal mol⁻¹) of **8f**, **8g**, **8h**, **8j**, and **8l** against EGFR and BRAF^{V600E}

Compound	EGFR (PDB ID: 1M17)	BRAF ^{V600E} (PDB ID: 4RZV)
8f	-6.13	-6.77
8g	-6.66	-7.97
8h	-6.63	-7.23
8j	-6.39	-7.07
8l	-6.3	-6.53
Erlotinib	-7.3	—
Vemurafenib	—	-10.53

examine **8g**'s capacity to cause apoptosis. Analysis of early and late apoptosis revealed that compound **8g** induced significant apoptosis, with a necrosis percentage of 4.39 (Fig. 6 and 7).

3.3. *In silico* docking simulation

This study conducted a thorough computer docking analysis to determine the binding relationships between chemicals **8f**, **8g**,




Fig. 8 3D closest interactions between active site amino acid residues of EGFR kinase (PDB ID: 1M17) and best docking score compound **8g**.




Fig. 9 Depicted 2D figures of binding interactions of compounds **8g** and **8h** within active site of BRAF^{V600E} (PDB ID: 4RZV) showing pi–H bonds as green-dotted lines with LYS 483, VAL 471, and SER 535.

8h, 8j, and 8l and EGFR-TK. The present study employed the Discovery Studio program to conduct a comprehensive analysis of the interaction mechanism.^{55,56} To improve this analysis, we incorporated the crystallographic structure of the EGFR-erlotinib complex, as documented in the Protein Data Bank (PDB ID: 1M17),^{42,57} to give the study a strong structural base, as well as the crystallographic configuration of EGFR complexed with Erlotinib. To test the docking technique's efficacy, we redocked the co-crystallized ligand erlotinib into the active site of the EGFR protein. The technique produced an S score of $-7.30 \text{ kcal mol}^{-1}$, indicating the procedure's precision. A strong hydrogen bond interaction was made between the pyrimidine nitrogen in Erlotinib and the amino acid residue Met769 in the EGFR structure, which made the docking result even more clear. This interaction is crucial for stabilizing the ligand in the active site, underscoring the significance of molecular interactions in the binding process. We docked compounds **8f**, **8g**, **8h**, **8j**, and **8l** with EGFR kinase to determine the binding affinity of derivatives with the best *in vitro* activity against EGFR, and Table 5 shows their docking scores.

All the tested compounds had a strong and similar ability to bind to erlotinib at the EGFR enzyme's active site. A visual analysis of the optimal docking pose was conducted to determine potential interactions between the test compounds and the amino acid residues constituting the active site. Fig. 8 illustrates how two H-bond interactions with MET 769 and a pi-H interaction with LEU 694 stabilized the structure of compound **8g**, which had the highest docking score among its congeners, within EGFR binding site.

The study's most effective antiproliferative hybrids, **8g** and **8h**, was looked at in more detail using *in silico* docking to find out how it binds to the active site of BRAF^{V600E}. This exploratory method utilized the crystal structure of BRAF^{V600E} in complex with Vemurafenib (PDB ID: 4RZV) as a reference point.^{43,58} Compounds **8g** and **8h** showed the highest binding affinity ($S = -7.97$ and $-7.23 \text{ kcal mol}^{-1}$; respectively) among their test

congeners, and visual inspection of their docking poses revealed a number of pi-H interactions *via* *N-p*-tolyl moiety and quinazoline ring with LYS 483 and VAL 471, in addition to triazole ring with SER 535, as shown in Fig. 9.

In summary, these docking experiments provide good insights into the potential inhibitory activity of these new quinazolines against EGFR and BRAF kinases, and their high binding affinity within test crystal structures suggesting that they can effectively interact with crucial amino acid residues of both kinases.

4. Conclusion

In search of novel antiproliferative scaffolds, we designed and synthesized twenty new 1,2,3-oxadiazole/quinazoline-4-one hybrids (**8a-t**) that inhibit both EGFR and BRAF^{V600E}. The novel hybrids showed promising antiproliferative activities. We investigated the inhibitory effects of derivatives **8f**, **8g**, **8h**, **8j**, and **8l** on EGFR and BRAF^{V600E}. *In vitro* experiments revealed that compounds **8g**, **8h**, and **8l** are effective cancer-fighting medicines that inhibit both EGFR and BRAF^{V600E}. Additionally, compounds **8g** and **8h** may have apoptotic action because they activated caspase 3, 8, and Bax while inhibiting Bcl2. Cell cycle analysis and apoptosis induction assays on **8g** revealed cell cycle arrest in the G1 phase. Docking experiments revealed structural insights, with compound **8g** exhibiting strong binding affinities for both EGFR and BRAF^{V600E}, as indicated by its high docking scores. Upon optimization, these novel hybrids may have the potential to act as anticancer agents.

Data availability

Samples of compounds **8a-t** are available from the authors.

Conflicts of interest

The author reported no potential conflicts of interest(s).

Acknowledgements

This work was funded by the Researchers Supporting Project Number (RSPD2024R603) King Saud University, Riyadh, Saudi Arabia. The authors also acknowledge support from the KIT Publication Fund of the Karlsruhe Institute of Technology.

References

- 1 A. Letai, *Annu. Rev. Cancer Biol.*, 2017, **1**, 275–294.
- 2 E. J. Lee, *Cystogenesis*, 2016, 25–34.
- 3 S. Zhu, T. Zhang, L. Zheng, H. Liu, W. Song, D. Liu, Z. Li and C.-x. Pan, *J. Hematol. Oncol.*, 2021, **14**, 156.
- 4 N. Lu, J. Wu, M. Tian, S. Zhang, Z. Li and L. Shi, *Eur. J. Med. Chem.*, 2024, 116233.
- 5 S. Sudhesh Dev, S. A. Zainal Abidin, R. Farghadani, I. Othman and R. Naidu, *Front. Pharmacol.*, 2021, **12**, 772510.
- 6 J. Esteban-Villarrubia, J. J. Soto-Castillo, J. Pozas, M. San Román-Gil, I. Orejana-Martín, J. Torres-Jiménez, A. Carrato, T. Alonso-Gordoa and J. Molina-Cerrillo, *Int. J. Mol. Sci.*, 2020, **21**, 8529.
- 7 L. H. Al-Wahaibi, A. M. Elshamsy, T. F. Ali, B. G. Youssif, S. Bräse, M. Abdel-Aziz and N. A. El-Koussi, *ACS Omega*, 2024, **9**(32), 34358–34369.
- 8 L. H. Al-Wahaibi, A. F. Mohammed, F. E.-Z. S. Abdel Rahman, M. H. Abdelrahman, X. Gu, L. Trembleau and B. G. Youssif, *J. Enzyme Inhib. Med. Chem.*, 2023, **38**, 2218602.
- 9 T. Notarangelo, L. Sisinni, V. Condelli and M. Landriscina, *Cancer Cell Int.*, 2017, **17**, 1–9.
- 10 S. Mondaca, M. Lacouture, J. Hersch and R. Yaeger, *JCO Precis. Oncol.*, 2018, **2**, 1800088.
- 11 M. Okaniwa, M. Hirose, T. Imada, T. Ohashi, Y. Hayashi, T. Miyazaki, T. Arita, M. Yabuki, K. Kakoi and J. Kato, *J. Med. Chem.*, 2012, **55**, 3452–3478.
- 12 Q. Zhang, Y. Diao, F. Wang, Y. Fu, F. Tang, Q. You and H. Zhou, *MedChemComm*, 2013, **4**, 979–986.
- 13 K. Laxmikeshav, P. Kumari and N. Shankaraiah, *Med. Res. Rev.*, 2022, **42**, 513–575.
- 14 B. K. Banik and B. Banerjee, *Heterocyclic Anticancer Agents*, Walter de Gruyter GmbH & Co KG, 2022.
- 15 M. Moradi, A. Mousavi, Z. Emamgholipour, J. Giovannini, S. Moghimi, F. Peytam, A. Honarmand, S. Bach and A. Foroumadi, *Eur. J. Med. Chem.*, 2023, 115626.
- 16 S. Sharma, K. Sharma, S. Pathak, M. Kumar and P. K. Sharma, *Open Med. Chem. J.*, 2020, **14**, 108–121.
- 17 K. Nepali, S. Sharma, R. Ojha and K. L. Dhar, *Med. Chem. Res.*, 2013, **22**, 1–15.
- 18 V. Panwar, K. Mukherji, M. Ghate, D. K. Jindal and D. Kumar, in *Biomedical Translational Research: Drug Design and Discovery*, Springer, 2022, pp. 387–399.
- 19 H. T. Abdel-Mohsen, M. M. Anwar, N. S. Ahmed, S. S. Abd El-Karim and S. H. Abdelwahed, *Molecules*, 2024, **29**, 875.
- 20 R. V. Patel, B. M. Mistry, A. V. Gujarati, A. B. Patel and D. K. Patel, *ChemistrySelect*, 2023, **8**, e202301053.
- 21 H. C. Kolb, M. Finn and K. B. Sharpless, *Angew. Chem., Int. Ed.*, 2001, **40**, 2004–2021.
- 22 M. Akter, K. Rupa and P. Anbarasan, *Chem. Rev.*, 2022, **122**, 13108–13205.
- 23 Z. Y. Wang, J. Li, N. Wang, H. Liu and K. K. Wang, *Asian J. Org. Chem.*, 2023, **12**, e202300105.
- 24 E. M. El-Sheref, S. Bräse, H. N. Tawfeek, F. A. Alasmary and B. G. Youssif, *Int. J. Mol. Sci.*, 2023, **24**, 13300.
- 25 E. M. El-Sheref, M. A. Elbastawesy, A. B. Brown, A. M. Shawky, H. A. Gomaa, S. Bräse and B. G. Youssif, *Molecules*, 2021, **26**, 6798.
- 26 M. A. Mahmoud, A. F. Mohammed, O. I. Salem, T. M. Almutairi, S. Bräse and B. G. Youssif, *J. Enzyme Inhib. Med. Chem.*, 2024, **39**, 2305856.
- 27 A. M. Mohamed, O. M. Abou-Ghadir, Y. A. Mostafa, K. A. Dahlous, S. Bräse and B. G. Youssif, *Front. Chem.*, 2024, **12**, 1447618.
- 28 E. Kucuksayan and T. Ozben, *Curr. Top. Med. Chem.*, 2017, **17**, 907–918.
- 29 H. A. Abou-Zied, E. A. Beshr, H. A. Gomaa, Y. A. Mostafa, B. G. Youssif, A. M. Hayallah and M. Abdel-Aziz, *Arch. Pharm.*, 2023, **356**, 2200464.
- 30 M. B. Alshammari, A. A. Aly, B. G. Youssif, S. Bräse, A. Ahmad, A. B. Brown, M. A. Ibrahim and A. H. Mohamed, *Front. Chem.*, 2022, **10**, 1076383.
- 31 L. H. Al-Wahaibi, H. A. Abou-Zied, E. A. Beshr, B. G. Youssif, A. M. Hayallah and M. Abdel-Aziz, *Int. J. Mol. Sci.*, 2023, **24**, 9104.
- 32 L. H. Al-Wahaibi, E. M. El-Sheref, M. M. Hammouda and B. G. Youssif, *Pharmaceuticals*, 2023, **16**, 467.
- 33 L. H. Al-Wahaibi, A. M. Gouda, O. F. Abou-Ghadir, O. I. Salem, A. T. Ali, H. S. Farghaly, M. H. Abdelrahman, L. Trembleau, H. H. Abdu-Allah and B. G. Youssif, *Bioorg. Chem.*, 2020, **104**, 104260.
- 34 L. H. Al-Wahaibi, M. Hisham, H. A. Abou-Zied, H. A. Hassan, B. G. Youssif, S. Bräse, A. M. Hayallah and M. Abdel-Aziz, *Pharmaceuticals*, 2023, **16**, 1522.
- 35 L. H. Al-Wahaibi, M. A. Mahmoud, Y. A. Mostafa, A. E. Raslan and B. G. Youssif, *J. Enzyme Inhib. Med. Chem.*, 2023, **38**, 376–386.
- 36 R. A. Mekheimer, S. M. Allam, M. A. Al-Sheikh, M. S. Moustafa, S. M. Al-Mousawi, Y. A. Mostafa, B. G. Youssif, H. A. Gomaa, A. M. Hayallah and M. Abdelaziz, *Bioorg. Chem.*, 2022, **121**, 105693.
- 37 M. Hisham, H. A. Hassan, H. A. Gomaa, B. G. Youssif, A. M. Hayallah and M. Abdel-Aziz, *J. Mol. Struct.*, 2022, **1254**, 132422.
- 38 S. A. El-Kalyoubi, H. A. Gomaa, E. M. Abdelhafez, M. Ramadan, F. Agili and B. G. Youssif, *Pharmaceuticals*, 2023, **16**, 716.
- 39 L. H. Al-Wahaibi, A. F. Mohammed, M. H. Abdelrahman, L. Trembleau and B. G. Youssif, *Molecules*, 2023, **28**, 1269.
- 40 B. G. Youssif, A. M. Mohamed, E. E. A. Osman, O. F. Abou-Ghadir, D. H. Elnaggar, M. H. Abdelrahman, L. Trembleau and H. A. Gomaa, *Eur. J. Med. Chem.*, 2019, **177**, 1–11.
- 41 H. A. El-Sherief, B. G. Youssif, S. N. A. Bukhari, A. H. Abdelazeem, M. Abdel-Aziz and H. M. Abdel-Rahman, *Eur. J. Med. Chem.*, 2018, **156**, 774–789.

42 M. A. Bhat, B. Tüzün, N. A. Alsaif, A. A. Khan and A. M. Naglah, *J. Mol. Struct.*, 2022, **1257**, 132600.

43 A. K. Singh, A. Kumar, S. Thareja and P. Kumar, *Anti-Cancer Agents Med. Chem.*, 2023, **23**, 278–297.

44 H. S. ElZahabi, M. S. Nafie, D. Osman, N. H. Elghazawy, D. H. Soliman, A. A. H. El-Helby, R. K. Arafa and E. J. of, *Med. Chem.*, 2021, **222**, 113609.

45 G. Moussa, R. Alaaeddine, L. M. Alaeddine, R. Nassra, A. S. Belal, A. Ismail, A. F. El-Yazbi, Y. S. Abdel-Ghany and A. Hazzaa, *Eur. J. Med. Chem.*, 2018, **144**, 635–650.

46 M. I. Mangione, R. A. Spanevello and M. Anzardi, *RSC Adv.*, 2017, **7**, 47681–47688.

47 H. A. El-Sherief, B. G. Youssif, A. H. Abdelazeem, M. Abdel-Aziz and H. M. Abdel-Rahman, *Anti-Cancer Agents Med. Chem.*, 2019, **19**, 697–706.

48 A. S. Borude, S. R. Deshmukh, S. V. Tiwari, S. H. Kumar and S. R. Thopate, *Eur. J. Med. Chem.*, 2024, **276**, 116727.

49 S. Elmore, *Toxicol. Pathol.*, 2007, **35**, 495–516.

50 M. S. D'arcy, *Cell Biol. Int.*, 2019, **43**, 582–592.

51 G. W. Foight, *Determinants of protein-peptide interaction specificity in the Bcl-2 and TRAF families*, Massachusetts Institute of Technology, 2015.

52 Y.-F. Chen, A.-S. Lee, W.-Y. Chen, C.-H. Lin, C.-L. Kuo and J.-G. Chung, *Am. J. Chin. Med.*, 2020, **48**, 719–736.

53 N. Naumova and R. Šachl, *Membranes*, 2020, **10**, 299.

54 K. G. Ponder and L. H. Boise, *Cell Death Discovery*, 2019, **5**, 56.

55 T. S. Ibrahim, R. M. Bokhtia, A. M. Al-Mahmoudy, E. S. Taher, M. A. AlAwadh, M. Elagawany, E. H. Abdel-Aal, S. Panda, A. M. Gouda and H. Z. Asfour, *Bioorg. Chem.*, 2020, **99**, 103782.

56 M. S. Shaykoon, A. A. Marzouk, O. M. Soltan, A. S. Wanas, M. M. Radwan, A. M. Gouda, B. G. Youssif and M. Abdel-Aziz, *Bioorg. Chem.*, 2020, **100**, 103933.

57 V. Jakhmola, T. Parashar, P. Ghildiyal, A. Ansori, R. K. Sharma, N. R. Rao, K. Kalra, N. Singh, N. Nainwal and R. K. Singh, *Pharmacogn. J.*, 2022, **14**, 4609–4629.

58 T. Kircher, T. Pantsar, A. Oder, J. P. von Kries, M. Juchum, B. Pfaffenrot, P. Kloevekorn, W. Albrecht, R. Selig and S. Laufer, *Eur. J. Med. Chem.*, 2021, **209**, 112901.

